PYPD · PolyPid Ltd. Ordinary Shares
View on chartInsiders & Stakes
No transactions found.
Transaction History
No transactions found.
No transactions found.
No transactions found.
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
PolyPid Ends Exclusive License with AdvanZ Pharma in Europe
PolyPid has agreed to terminate its 2022 exclusive license, distribution, and supply agreement with AdvanZ Pharma for the D‑Plex 100 product in Europe. The decision ends a partnership that had granted PolyPid exclusive rights to market the drug in the region. This change may alter PolyPid’s European sales and supply chain dynamics. The company’s stock is currently trading within its 52‑week range.
PolyPid Ends Exclusive License with AdvanZ Pharma in Europe. PolyPid has agreed to terminate its 2022 exclusive license, distribution, and supply agreement with AdvanZ Pharma for the D‑Plex 100 product in Europe. The decision ends a partnership that had granted PolyPid exclusive rights to market the drug in the region. This change may alter PolyPid’s European sales and supply chain dynamics. The company’s stock is currently trading within its 52‑week range.